Remove 2013 Remove Licensing Remove Regulations
article thumbnail

Navigating Regulatory Hurdles in Drug Development

DrugBank

Drug development is a complex and highly regulated process. While these regulations protect public health, they also introduce significant challenges for pharmaceutical researchers. This means pharmaceutical companies must remain vigilant and adaptable to comply with evolving regulations. Regulatory agencies, such as the U.S.

article thumbnail

Federal Marijuana Rescheduling: States Get Ready

FDA Law Blog: Biosimilars

Governors, state cannabis regulators, law enforcement groups and local governments weighed in, as did marijuana advocates and opponents, marijuana industry associations, Members of Congress, federal law enforcement groups, healthcare and human rights groups, unions and trade associations, and private individuals.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

Cell Mol Immunol 10(1):21-9 (2013). Normality sensing licenses local T cells for innate-like tissue surveillance. Regulation of cutaneous malignancy by gammadelta T cells. Chem Immunol Allergy 86:151-183 (2005). Kalyan S, Kabelitz D. Defining the nature of human γδ T cells: a biographical sketch of the highly empathetic.

Therapies 105
article thumbnail

DOJ Investigates $250 Million in U.S. Sales of Counterfeit Drugs Using Fake DSCSA Pedigrees

Policy Prescription

from licensed pharmacies to American patients. Instead, it had everything to do with licensed U.S. Even worse, it showed flaws in our domestic system of drug regulation, notably the Drug Supply Chain Security Act of 2013 (DSCSA). However, to do that, the regulations must prevent the creation of fake DSCSA pedigrees.

article thumbnail

Q&A: The IND Journey Phase I – Navigating Success

Advarra

The standard for the audit used depends on the type of vendor and would include the applicable regulations and ICH guidelines. The term drug substance and drug product are found in the NDA regulations 21 CFR 314.3, A: For FDA 1572 is a Statement of Investigator under US Regulations/Laws. of this guidance. of this guidance.

article thumbnail

Article FDA Thank You In proposed rule, FDA offers up a (surprisingly sparse) list of drugs that present demonstrable compounding difficulties

Agency IQ

This proposed rule has been in the works for over 20 years, during which time the regulation of drug compounding has gone through many changes. An “outsourcing facility” per Section 503B is a registered location that engages in the compounding of sterile drugs but is not required to be a licensed pharmacy.

FDA 40
article thumbnail

Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

The Pharma Data

In February, the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) accepted the company’s Supplemental Biologics License Application (sBLA) and Marketing Authorization Application (MAA), respectively, for ofatumumab for the treatment of relapsing forms of multiple sclerosis in adults. Adv Studies Pharm. Types of MS.

Trials 52